News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Champions Oncology, Inc. (CSBR) Schedules Fourth Quarter And Fiscal Year 2017 Earnings Call



7/17/2017 10:16:38 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

HACKENSACK, N.J., July 17, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year ended April 30, 2017, on Thursday, July 27, 2017, after market close.

The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). To participate in the call, please call 866-682-6100 (domestic) or 862-255-5401 (international) ten minutes ahead of the call and give the verbal reference "Champions Oncology."

A replay of the call will be available on the Investor tab of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company's TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.

View original content:http://www.prnewswire.com/news-releases/champions-oncology-schedules-fourth-quarter-and-fiscal-year-2017-earnings-call-300488841.html

SOURCE Champions Oncology, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES